Radiation recall dermatitis with dabrafenib and trametinib: A case report
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/5275/celik%2c%20ugur_2020.pdf.jpg?sequence=8&isAllowed=y)
View/ Open
Access
info:eu-repo/semantics/openAccessAttribution-NonCommercial 4.0 Internationalhttps://creativecommons.org/licenses/by-nc/4.0/Date
2020Metadata
Show full item recordCitation
Yılmaz, M., Çelik, U. ve Hasçiçek, S. (2020). Radiation recall dermatitis with dabrafenib and trametinib: A case report. World Journal of Clinical Cases, 8(3), 522-526. https://dx.doi.org/10.12998/wjcc.v8.i3.522Abstract
BACKGROUND Radiation recall dermatitis has been defined as the “recalling” by skin of previous radiation exposure in response to the administration of certain response-inducing drugs. Although the phenomenon is relatively well known in the medical world, an exact cause has not been documented. CASE SUMMARY Here, we report the rare occurrence of radiation recall dermatitis after palliative radiotherapy for bone metastases in a metastatic melanoma patient treated with a combination of dabrafenib and trametinib. CONCLUSION We present a case of radiation recall dermatitis after completion of palliative radiotherapy while being treated with a combination of dabrafenib and trametinib. This is a very rare toxic event, and there is insufficient data to describe prevention strategies. Increased awareness and reporting of cases will help to better explain the association between targeted therapy and the radiation recall phenomenon.
WoS Q Kategorisi
Q3xmlui.dri2xhtml.METS-1.0.item-scopusquality
Q3Source
World Journal of Clinical CasesVolume
8Issue
3Collections
- Makale Koleksiyonu [3790]
- PubMed İndeksli Yayınlar Koleksiyonu [4251]
- Scopus İndeksli Yayınlar Koleksiyonu [6601]
- WoS İndeksli Yayınlar Koleksiyonu [6677]
The following license files are associated with this item: